HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alcresta Launches With Dynamic Business Model; Raises $10M Series A

This article was originally published in The Pink Sheet Daily

Executive Summary

Former Alnara executives have come together with the company’s previous investors to launch two start-ups focusing on enzyme therapies.

You may also be interested in...



Alnara Execs Start Anew With Allena; $15 M Series A

Former Alnara founders Alexey Margolin and Robert Gallotto have begun a new venture that includes Alnara’s previous investors.

Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy

Alnara hopes to leverage Lilly's prior success with recombinant insulin products.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS124657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel